更新于：2024-12-21
N-acetyl-D-mannosamine
更新于：2024-12-21
概要
基本信息
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构
分子式C8H15NO6 |
InChIKeyMBLBDJOUHNCFQT-WCTZXXKLSA-N |
CAS号3615-17-6 |
关联
9
项与 N-acetyl-D-mannosamine 相关的临床试验An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis
An open-label, randomised, three-arm crossover study to examine the comparative pharmacokinetics of ManNAc administered as an oral solution and as two novel oral tablet formulations in healthy adult males
An open-label, randomised, two-arm crossover study to determine the absolute oral bioavailability of ManNAc in healthy adult males
100 项与 N-acetyl-D-mannosamine 相关的临床结果
登录后查看更多信息
100 项与 N-acetyl-D-mannosamine 相关的转化医学
登录后查看更多信息
100 项与 N-acetyl-D-mannosamine 相关的专利（医药）
登录后查看更多信息
158
项与 N-acetyl-D-mannosamine 相关的文献（医药）2024-12-31Gut microbes
Integrative analysis with microbial modelling and machine learning uncovers potential alleviators for ulcerative colitis
Article
作者: Zhu, Jinlin ; Chen, Wei ; Lu, Wenwei ; Zhang, Hao ; Hu, Mingyi ; Chen, Jing ; Yin, Jialin ; Wang, Hongchao
Ulcerative colitis (UC) is a challenging form of inflammatory bowel disease, and its etiology is intricately linked to disturbances in the gut microbiome. To identify the potential alleviators of UC, we employed an integrative analysis combining microbial community modeling with advanced machine learning techniques. Using metagenomics data sourced from the Integrated Human Microbiome Project, we constructed individualized microbiome community models for each participant. Our analysis highlighted a significant decline in both α and β-diversity of strain-level microbial populations in UC subjects compared to controls. Distinct differences were also observed in the predicted fecal metabolite profiles and strain-to-metabolite contributions between the two groups. Using tree-based machine learning models, we successfully identified specific microbial strains and their associated metabolites as potential alleviators of UC. Notably, our experimental validation using a dextran sulfate sodium-induced UC mouse model demonstrated that the administration of Parabacteroides merdae ATCC 43,184 and N-acetyl-D-mannosamine provided notable relief from colitis symptoms. In summary, our study underscores the potential of an integrative approach to identify novel therapeutic avenues for UC, paving the way for future targeted interventions.
2024-09-04RSC Advances
Soft X-ray spectromicroscopy of human fibroblasts with impaired sialin function.
Article
作者: Miinalainen, Ilkka ; Darin, Niklas ; Kangas, Salla M ; Uusimaa, Johanna ; Patanen, Minna ; Angervaniva, Pia ; Blomqvist, Maria ; Huttula, Marko ; Hinttala, Reetta ; Mansikkala, Tuomas
Salla disease (SD) is a lysosomal storage disease where free sialic acid (SA) accumulates in lysosomes due to the impaired function of a membrane protein, sialin. Synchrotron radiation-based scanning transmission soft X-ray spectromicroscopy (STXM) was used to analyze both SD patients' fibroblasts and normal human dermal fibroblasts (NHDF) from healthy controls. Both cell lines were also cultured with N-acetyl-d-mannosamine monohydrate (ManNAc) to see if it increased SA concentration in the cells. The STXM technique was chosen to simultaneously observe the morphological and chemical changes in cells. It was observed that free SA did not remain in the lysosomes during the sample processing, leaving empty vacuoles to the fibroblasts. The total cytosol and entire cell spectra, however, showed systematic differences between the SD and NHDF samples, indicating changes in the relative macromolecular concentrations of the cells. The NHDF cell lines contained a higher relative protein concentration compared to the SD cell lines, and the addition of ManNAc increased the relative protein concentration in both cell lines. In this study, two sample preparation methods were compared, resin-embedded thin sections and cells grown directly on sample analysis grids. While the samples grown on the grids exhibited clean, well-resolved spectra not masked by embedding resin, the low penetration depth of soft X-rays hindered the analysis to only the thin region of the microfilaments away from the thick nucleus.
2024-08-01Clinical Pharmacology in Drug Development
Impact of Food on the Oral Absorption of N‐Acetyl‐D‐Mannosamine in Healthy Men and Women
Article
作者: Gahl, William A. ; Meola, Tahlia R. ; Fornasini, Gianfranco ; Reuter, Stephanie E. ; Evans, Allan M. ; Polasek, Thomas M. ; Huizing, Marjan
Abstract:
N‐Acetyl‐D‐mannosamine (ManNAc) is an endogenous monosaccharide and precursor of N‐acetylneuraminic acid (Neu5Ac), a critical sialic acid. ManNAc is currently under clinical development to treat GNE myopathy, a rare muscle‐wasting disease. In this randomized, open‐label, 2‐sequence, crossover study, 16 healthy women and men were administered a single oral dose of ManNAc under fasting and fed conditions. Blood samples were collected for 48 hours after dosing for quantification of plasma ManNAc and Neu5Ac concentrations. Noncompartmental pharmacokinetic and deconvolution analyses were performed using baseline‐corrected plasma concentration data. Administration of ManNAc in the fed state resulted in a 1.6‐fold increase in ManNAc exposure, compared to fasting conditions. A concurrent increase in Neu5Ac exposure was observed in the presence of food. Deconvolution analysis indicated that the findings were attributed to prolonged absorption rather than an enhanced rate of absorption. The impact of food on ManNAc pharmacokinetics was greater in women than men (fed/fasted area under the concentration‐time curve from time 0 to infinity mean ratio: 198% compared to 121%). It is hypothesized that the presence of food slows gastric emptying, allowing a gradual release of ManNAc into the small intestine, translating into improved ManNAc absorption. The results suggest that taking ManNAc with food may enhance its therapeutic activity and/or reduce the daily dosage requirement.
100 项与 N-acetyl-D-mannosamine 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 远端性肌病 | 临床3期 | - | - | |
| 远端性肌病 | 临床3期 | - | - | |
| 局灶性节段性肾小球硬化症 | 临床2期 | 美国 | 2024-12-25 | |
| 遗传性包涵体肌病 | 临床2期 | 美国 | 2015-02-05 | |
| 肾脏疾病 | 临床1期 | 美国 | 2016-07-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 12 | 淵選壓選壓築築糧餘範(範窪製選齋範顧鏇觸膚) = 夢鬱構築艱範膚構齋遞 鑰壓醖糧鏇鬱襯夢齋觸 (窪衊廠範顧鑰願鬱壓醖 ) | 积极 | 2021-11-01 | |||
临床1期 | 7 | ManNAc 3g single dose | 膚鏇積顧廠鑰夢壓築齋(遞夢糧鑰鏇艱鏇觸壓鏇) = There were no serious adverse events. Most subjects (5 of 6) that received ManNAc twice daily showed a marked reduction in urine PCR (26-54%), which correlated with the degree of glomerular hyposialylation 蓋顧襯簾鏇範鹹醖襯壓 (鏇獵衊鏇繭膚鹹鬱範窪 ) 更多 | 积极 | 2020-10-19 | ||
临床2期 | 12 | (ManNAc: Cohort A) | 淵襯簾鑰鹹積窪膚齋淵(衊糧範蓋醖膚壓憲繭範) = 齋糧壓鬱網遞網壓簾膚 窪齋衊衊顧艱獵淵範築 (簾蓋繭壓積壓簾醖鬱糧, 齋構醖膚齋積選繭網築 ~ 糧衊築壓鹹鏇繭壓壓膚) 更多 | - | 2019-04-16 | ||
(ManNAc: Cohort B) | 淵襯簾鑰鹹積窪膚齋淵(衊糧範蓋醖膚壓憲繭範) = 鬱醖餘築繭範選鹽鹹鏇 窪齋衊衊顧艱獵淵範築 (簾蓋繭壓積壓簾醖鬱糧, 鹹繭構遞鑰鹹願襯鏇繭 ~ 糧積壓願憲糧襯鏇簾鏇) 更多 | ||||||
N/A | 微小病变性肾病 Angptl4 | NPHS2-Angptl4 | PAN | - | 網鹽齋夢鹹壓鹽餘繭壓(製艱衊積壓簾艱積網鑰) = 窪夢顧觸醖繭製鹽衊築 鬱願襯壓鏇憲構願願蓋 (壓鏇膚憲築選願憲醖繭 ) | 积极 | 2010-11-16 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用